Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Concerns over cardiac side effects are the largest single cause of compound attrition during pharmaceutical drug development. For a number of years, biophysically detailed mathematical models of cardiac electrical activity have been used to explore how a compound, interfering with specific ion-channel function, may explain effects at the cell-, tissue- and organ-scales. With the advent of high-throughput screening of multiple ion channels in the wet-lab, and improvements in computational modelling of their effects on cardiac cell activity, more reliable prediction of pro-arrhythmic risk is becoming possible at the earliest stages of drug development. In this paper, we review the current use of biophysically detailed mathematical models of cardiac myocyte electrical activity in drug safety testing, and suggest future directions to employ the full potential of this approach.

Original publication

DOI

10.1111/j.1476-5381.2012.02020.x

Type

Journal article

Journal

Br J Pharmacol

Publication Date

11/2012

Volume

167

Pages

932 - 945

Keywords

Animals, Arrhythmias, Cardiac, Computer Simulation, Drug Evaluation, Preclinical, Drug-Related Side Effects and Adverse Reactions, Electrophysiologic Techniques, Cardiac, Heart, Humans, Ion Channels, Models, Cardiovascular